Business
-
Cystic Fibrosis Foundation Therapeutics (CFFT), a nonprofit associated with the Cystic Fibrosis Foundation, has announced that it will provide Shire with up to $15 million for development of an aerosol messenger RNA therapy designed to… Read more . . .
-
Pfizer has launched Novartis’ Ultibro Breezhaler indacaterol/glycopyrronium DPI for the treatment of COPD in the UK, the company said. Ultibro Breezhaler was approved in Europe in September 2013. In September 2014, Pfizer announced that it… Read more . . .
-
Meda Pharmaceuticals and Cipla have filed suit against Apotex in the Delaware Federal District Court, claiming that Apotex’s submission of an ANDA for a generic version of Dymista azelastine HCl/fluticasone propionate nasal spray violates patents… Read more . . .
-
Avanir Pharmaceuticals, which just received a complete response letter from the FDA for its AVP-825 intranasal sumatriptan powder, has announced that it will be acquired by Otsuka Pharmaceutical for approximately $3.5 billion. Avanir will become… Read more . . .
-
Skyepharma has announced that Mundipharma has launched the Flutiform fluticasone/formoterol MDI for the treatment of asthma in Spain, triggering a milestone payment of €2.0 million. In addition, Mundipharma marketing partner Zambon Italia has now launched… Read more . . .
-
Endo International has acquired exclusive US and Mexican rights to Trimel BioPharma’s Natesto testosterone nasal gel, which was approved by the the FDA in May 2014 as a replacement treatment for men with low levels… Read more . . .
-
GSK Australia has announced that it plans to invest AUD31 million in blow-fill-seal equipment for the manufacture of Venolin salbutamol nebules at its facility in Boronia, a suburb of Melbourne. The company cited increasing demand… Read more . . .
-
The US Patent and Trademark Office (USPTO) has awarded US Patent No 8,883,728, “Intranasal administration of active agents to the central nervous system,” to Aegis Therapeutics, the company said. The patent covers, “Pharmaceutical compositions and… Read more . . .
-
As AstraZeneca completes the acquisition of Almirall’s respiratory drug franchise, which was first announced in July 2014, Almirall says that 719 employees will transfer to AstraZeneca. The deal includes the inhalation R&D company Almirall Sofotec… Read more . . .
-
Impax Laboratories has reported a 19.1% increase in total revenues for the quarter ended September 30, 2014 compared to the third quarter of the prior year. The company attributes a portion of the increase in… Read more . . .
Featured event:

Upcoming Events
Sponsored by Intertek,, hosts of
The Inhaled & Nasal Biologics | DNA Forum
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
October 19-October 20: MVIC Autumn Training 2026, Lund, Sweden
October 21-October 22: MVIC Symposium, Lund, Sweden
October 28-October 30: Deutches Aerosol Therapie Symposium (DATS), Marburg, Germany
November 10-November 11: Rescon Europe 2026, Porto, Portugal
December 9-December 11: DDL 2026, Edinburgh, Scotland



